Table 3.
The disease-modifying therapies approved by Health Canada to treat multiple sclerosis (1995/6–2017): drug name (brand/generic), drug identification number, mode of administration (injectable, oral, intravenous), Health Canada approval date.
| Disease-modifying therapy | Drug identification number | Mode of administration | Health Canada approval date |
|---|---|---|---|
| Betaseron® (IFNB-1b) | 02169649 | Injectable | July 1995 |
| Extavia® (IFNB-1b) | 02337819 | Injectable | November 2009 |
| Avonex® (IFNB-1a) | 02237770 | Injectable | April 1998 |
| 02269201 | |||
| 02267594 | |||
| Rebif® (IFNB-1a) | 02281708 | Injectable | February 1998 |
| 02277492 | |||
| 02237317 | |||
| 02237319 | |||
| 02237320 | |||
| 02277492 | |||
| 02281708 | |||
| 02318253 | |||
| 02318261 | |||
| 02318288 | |||
| Plegridy® (Peg-IFNB-1a) | 02444372 | Injectable | August 2015 |
| 02444380 | |||
| 02444399 | |||
| 02444402 | |||
| Copaxone® (glatiramer acetate) | 02233014 | Injectable | October 1997 |
| 02245619 | |||
| 02456915 | |||
| 02441446 | |||
| 02481510 | |||
| Glatect® (glatiramer acetate) | 02460661 | Injectable | August 2017 |
| Tysabri® (natalizumab) | 02286386 | Intravenous | September 2006 |
| Gilenya® (fingolimod) | 02365480 | Oral | March 2011 |
| 02482533 | |||
| Tecfidera® (dimethyl fumarate) | 02404508 | Oral | April 2013 |
| 02420201 | |||
| Aubagio® (teriflunomide) | 02416328 | Oral | November 2013 |
| Lemtrada® (alemtuzumab) | 02418320 | Intravenous | December 2013 |
| Zinbryta® (daclizumab) | 02459620 | Injectable | December 2016 |
| 02459639 | |||
| Ocrevus® (ocrelizumab) | 02467224 | Intravenous | August 2017 |
The DMDs listed represented all those available (approved) for use in MS by Health Canada at some point during the study. Daclizumab was withdrawn from the market in March 2018 due to safety concerns.